מדיטבין 200 מ"ג

Kraj: Izrael

Język: hebrajski

Źródło: Ministry of Health

Składnik aktywny:

GEMCITABINE AS HYDROCHLORIDE 200 MG/VIAL

Dostępny od:

MEDISON PHARMA LTD

Kod ATC:

L01BC05

Forma farmaceutyczna:

POWDER FOR SOLUTION FOR INFUSION

Droga podania:

I.V

Wyprodukowano przez:

INTAS PHARMACEUTICALS LTD, INDIA

Grupa terapeutyczna:

GEMCITABINE

Wskazania:

Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Data autoryzacji:

2012-11-01